CClinicalTrials.gg
CompletedNCT04533035INVOHVUpdated Mar 2, 2021

Lower Limb Tissue Oxygenation Using Near-infrared Spectroscopy During Hallux Valgus Operation

An observational study in Lower Limb Ischemia, sponsored by Kuopio University Hospital. Completed at 1 site in Finland. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2021-03-02.

Sponsored by Kuopio University Hospital · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
30
Ages
18 Years to 80 Years
Sex
All
01

Study summary

In acute lower limb ischemia the main goal of the treatment is to restore the blood before irreversible damage to the soft tissues of the limb. Delays in identifying acute lower limb ischemia may lead to limb loss or lead to the loss of the patient. Situations in which the patient is unable to express symptoms of the acute lower limb ischemia, such as during general anesthesia, in intensive care, or immediately after vascular surgery, are challenging for medical staff to identify. A reliable, easy-to-use and non-invasive monitoring method is not yet in every day use. The aim of this study is to demonstrate that Near InfraRed Spectroscopy (NIRS) monitoring is such a monitoring method.

Tourniquet induced ischemia is often used in hallux valgus surgery because it offers a bloodless view of the anatomical structures. In our study we will measure the soft tissue perfusion (rSO2) of the lower limbs during the whole operation. The sensors based on near-infrared spectroscopy will be located to the tibial surface and will record the normal state before the start of the tourniquet, during the tourniquet and also in the recovery phase.

The hypothesis is that rSO2 decreases linearly as a function of time from the beginning of the tourniquet induced ischemia and the recovery time depends on the duration of the tourniquet. In our study the patients will be operated under a spinal anesthesia. We also hypothesise that rSO2 increases due to the induction of the spinal anesthesia. Our goal is to define the percentual decline of rSO2 that is significant for lower limb ischemia and also its time response to induction of ischemia.

02

Conditions studied

  • Lower Limb Ischemia

Keywords

  • NIRS Spectroscopy
  • Lower Limb
  • Ischemia
  • Adults
03

In context

Hallux Valgus

144 studies on the registry are indexed under Hallux Valgus; 31 are open to participants now.

This study's enrollment of 30 is below the median of 50 across 35 observational studies indexed under Hallux Valgus.

Browse Hallux Valgus studies →

Lead sponsor

Kuopio University Hospital is the lead sponsor of 132 studies on the registry; 23 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Operative hallux valgus patients in Kuopio University Hospital.

Inclusion criteria

  • Patient understands the meaning of the study and related measures.
  • Patient gives his or her written informed consent.
  • A tourniquet is used.
  • The procedure is performed under spinal anesthesia.
  • Body mass index under 40.

Exclusion criteria

Exclusion Criteria:

  • Patient belongs to any of the following special groups: disabled people, minor, pregnant or breast feeding women, convicts, forensic psychiatric patients.
  • Previous lower limb vascular surgery.
  • Previous lower limb deep vein thrombosis.
  • Previously performed tibial fasciotomies.
  • Any another reason why the researcher considers that the patient is not suitable for the study.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
30 participants (actual)
Patient registry
No

Groups and cohorts

  • Single cohort

    30 patients undergoing hallux valgus surgery

06

What researchers measure

Primary outcomes

  1. The percentual decrease of the regional oxygen saturation in the lower limb 15 minutes after the tourniquet is applied.

    50% decrease from baseline NIRS value in 15 minutes

    Time frame: 15 minutes from tourniquet application

Secondary outcomes

  1. The time that the regional oxygen saturation in the lower limb takes to recover after the tourniquet is released.

    The time to NIRS value to reach baseline value after tourniquet is released

    Time frame: From the moment tourniquet is released to the point that NIRS value reaches it's baseline or patient is mobilised in the recovery room, whichever came first, assessed up to two hours.

  2. The percentual increase of the regional oxygen saturation in the lower limbs due to the induction of a spinal anesthesia.

    10% increase in NIRS value after 30 minutes after spinal anesthesia induction

    Time frame: 30 minutes from induction of spinal anesthesia

07

Study locations

1 site
  • Kuopio University Hospital
    Kuopio, 70100, Finland
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 2, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04533035
Lead sponsor
Kuopio University Hospital
Responsible party
Anna Govenius (Specialist in cardiothoracic surgery, MD, Kuopio University Hospital) — Principal investigator
First posted
Aug 31, 2020
Start date
Aug 28, 2020
Primary completion
Feb 26, 2021
Completion
Feb 26, 2021
Last update
Mar 2, 2021

Study contacts

Kimmo Mäkinen, docent
study director · Kuopio University Hospital
Anna H Govenius, MD
principal investigator · Kuopio University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion